A proportion of patients with drug-resistant tuberculosis (TB) receive ineffective treatment due to misdiagnosis by rapid molecular tests, according to a genomic analysis carried out in southern Mozambique and co-led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa" Foundation, and the Institute of Biomedicine in Valencia (IBV), from the Spanish National Research Council (CSIC). The results indicate that new molecular tests need to be developed to detect a wider range of mutations that confer resistance to first-line TB drugs.

The approach, which combines a simple-to-use molecular test with the minimally invasive autopsy, could be a valuable tool in regions with high burden of the disease

A study explores why the global estimates for tuberculosis mortality differ according to the institution that provides them